Bellevue Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Bellevue Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-129	Closed	-$1.02K	–	475
2025 Q1	$1.02K	Hold	129	–	–	﹤0.01%	473
2024 Q4	$1.63K	Hold	129	–	–	﹤0.01%	459
2024 Q3	$1.8K	Buy	129 +36	+39%	+$514	﹤0.01%	424
2024 Q2	$1.28K	Hold	93	–	–	﹤0.01%	449
2024 Q1	$1.54K	Hold	93	–	–	﹤0.01%	436
2023 Q4	$1.36K	Hold	93	–	–	﹤0.01%	434
2023 Q3	$1.14K	Hold	93	–	–	﹤0.01%	443
2023 Q2	$1.11K	Buy	+93	New	+$1.22K	﹤0.01%	472
2023 Q1	–	Sell	-62	Closed	-$1.31K	–	490
2022 Q4	$1.31K	Hold	62	–	–	﹤0.01%	457
2022 Q3	$1K	Buy	+62	New	+$1.32K	﹤0.01%	464

Other funds holding DAWN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Asset Management's DAWN Position: Q2 2025 in Review

Bellevue Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 129 shares — an estimated $1.02K sold.

Bellevue Asset Management first reported a position in DAWN in Q3 2022 and held it in 10 quarters. The position peaked at $1.8K in Q3 2024. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

Bellevue Asset Management reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
Bellevue Asset Management sold 129 Day One Biopharmaceuticals shares in Q2 2025, an estimated $1.02K.
Bellevue Asset Management first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 10 quarters.
Bellevue Asset Management's Day One Biopharmaceuticals position peaked at $1.8K in Q3 2024.
174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on Bellevue Asset Management's 13F filing for Q2 2025, filed 23 Jul 2025.